CoChat

Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how?

Trébucq, A., Enarson, D.A., Chiang, C.Y., Van Deun, A., Harries, A.D., Boillot, F., Detjen, A., Fujiwara, P.I., Graham, S.M., Monedero, I., Rusen, I.D., Rieder, H.L. · 2011 · The International Journal of Tuberculosis and Lung Disease
Cited by 126

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Abstract

Xpert ® MTB/RIF offers new and important possibilities for the diagnosis of sputum smear-negative tuberculosis (TB) and/or rifampicin (RMP) resistance, and many are encouraging rapid and widespread implementation. This simple test can be implemented almost everywhere, and it provides results within a few hours. In low-income countries (LICs), however, its cost, environmental limitations (stable and regular electricity, adequate room temperature) and difficulties involved in supply and maintenance are major obstacles. While it may be suitable for major reference hospitals, operational research is needed to evaluate the test and its additional yield above high-quality smear microscopy and clinical algorithms before its use at the peripheral level. In the meantime, direct microscopy should remain the initial diagnostic test for TB suspects. In most LICs, the prevalence of RMP resistance among new TB patients is very low; an Xpert MTB/RIF result indicating RMP resistance will thus always need confirmation by another test. In a population at high risk of RMP resistance (> 15%), however, the positive predictive value for RMP resistance by Xpert MTB/RIF is high, and identification of RMP resistance is an excellent proxy for multidrug-resistant TB (MDR-TB). The assay should be widely used for this purpose if, and only if, excellent MDR-TB management is available, both for ethical reasons and to reduce the risk of extensively drug-resistant TB.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.5588/ijtld.11.0392

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 126

Metadata

Authors
Trébucq, A., Enarson, D. A., Chiang, C. Y., Van Deun, A., Harries, A. D., Boillot, F., Detjen, A., Fujiwara, P. I., Graham, S. M., Monedero, I., Rusen, I. D., & Rieder, H. L.
Venue
The International Journal of Tuberculosis and Lung Disease
Published
2011-12-01
Volume
15
Issue
12
Pages
1567-1572
ISSN
1027-3719 (ISSN-L)
OpenAlex
W1971252437
Cited by
126
References
1
FWCI
10.41
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? https://app.cochat.ai/papers/10.5588/ijtld.11.0392
The paper
Trébucq, A., Enarson, D. A., Chiang, C. Y., Van Deun, A., Harries, A. D., Boillot, F., Detjen, A., Fujiwara, P. I., Graham, S. M., Monedero, I., Rusen, I. D., & Rieder, H. L. (2011). Xpert® MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? The International Journal of Tuberculosis and Lung Disease. https://doi.org/10.5588/ijtld.11.0392

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.